Do I Need Allergy Shots? When Medication Isn't Enough to Control Allergies

Consider allergy shots when your allergies require more than you're getting from medications alone. Specific signals that step 4 immunotherapy is warranted: you're using a daily antihistamine AND a nasal corticosteroid consistently, and your symptoms still significantly affect your sleep, work performance, outdoor activities, or mood. You're taking 3 or more allergy medications daily and still suffering. You've had 4 or more sinus infections in the past year. You've developed asthma alongside your allergies. Your medication is causing side effects you can't tolerate (nosebleeds from nasal steroids, sedation from antihistamines). Or you want the disease-modification benefit of preventing progression — particularly relevant for parents of children with rhinitis who want to prevent asthma development. Any of these factors justifies an allergist consultation to discuss immunotherapy.

When patients say their allergy medications 'stopped working,' the explanation is usually one of three things. First, the most common: pharmacotherapy was never truly optimized — antihistamines alone without nasal steroids, or sporadic rather than daily use. Genuinely trying optimized combination therapy (daily antihistamine + daily nasal steroid for a full season) sometimes resolves the apparent treatment failure. Second: new allergen sensitization has developed, meaning new triggers not covered by your current avoidance strategies are now driving symptoms. Third: disease progression — allergic rhinitis naturally worsens in some patients over time, increasing the symptom burden beyond what pharmacotherapy can adequately suppress. In the second and third scenarios, immunotherapy addresses the underlying IgE-mediated mechanism rather than just suppressing symptoms, making it the appropriate next step.

Yes — this is one of the most compelling disease-modification benefits of allergy immunotherapy, particularly in children. Patients with allergic rhinitis have a 3.5 times increased risk of developing asthma compared to the general population, per data published by Shaaban et al. in the Lancet (2008). The PAT study demonstrated that children aged 6-14 with allergic rhinitis who received immunotherapy had approximately 50% less asthma development over 10 years compared to children treated with pharmacotherapy alone. In adults, the data is less robust but immunotherapy has been shown to reduce asthma exacerbations and improve asthma control in allergic asthma patients. The preventive case for immunotherapy is strongest in children at the rhinitis phase of the allergic march — before asthma has developed — and in patients with multiple allergen sensitizations who show the greatest natural tendency toward progressive disease.

Generally no — mild allergy symptoms that are well-controlled with minimal medication do not typically meet the clinical threshold for immunotherapy. The ARIA stepped care framework positions immunotherapy for patients with moderate-to-severe disease inadequately controlled at steps 1-3. Mild intermittent allergies (symptoms present fewer than 4 days per week or fewer than 4 consecutive weeks, with minimal quality of life impact) are managed adequately with as-needed antihistamines without proceeding to immunotherapy. However, two situations might justify immunotherapy even in mild disease: first, if you strongly prefer a treatment that may provide lasting benefit without indefinite medication use; second, in children with mild current rhinitis but strong risk factors for asthma progression (family history of asthma, multiple sensitizations, early eczema onset), where early disease modification may prevent significant future disease. Discuss this preventive rationale with your allergist.

Allergic rhinitis and chronic or recurrent sinusitis are closely linked: approximately 80% of patients with chronic sinusitis have evidence of allergic sensitization. Signs that your sinusitis may be allergy-driven: episodes cluster around your known allergy seasons (spring tree pollen, fall ragweed), you have accompanying sneezing, itchy eyes, and nasal congestion typical of allergic rhinitis, and you get relief from antihistamines between infections. Recurrent sinusitis in the setting of allergic rhinitis — four or more episodes per year — is a specific indication that standard pharmacotherapy is inadequate and immunotherapy escalation is warranted. When allergic inflammation of the nasal mucosa is not adequately controlled, the drainage pathways from the sinuses become blocked more frequently, leading to recurrent bacterial superinfection. Treating the underlying allergy through immunotherapy can break this cycle more effectively than repeated antibiotic courses alone.

Yes — allergic asthma alongside allergic rhinitis is a particularly strong indication for immunotherapy. Both conditions share the underlying IgE-mediated mechanism, meaning immunotherapy addresses the root cause of both simultaneously. Multiple studies demonstrate that allergy shots improve asthma control, reduce rescue inhaler use, and decrease asthma exacerbations in patients with allergic asthma — in addition to the rhinitis benefits. The ARIA guidelines and GINA asthma guidelines both recognize allergic asthma as an indication for allergen immunotherapy. The one important prerequisite: your asthma must be well-controlled before starting immunotherapy (FEV1 at or above 70% predicted). Shots are not administered during active asthma flares or when your breathing is compromised. Managing asthma with appropriate controller medication first, then starting immunotherapy from a position of controlled disease, is the right clinical sequence.